| 1. |
- Ruilope, LM, et al.
(författare)
-
Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial
- 2019
-
Ingår i: American journal of nephrology. - : S. Karger AG. - 1421-9670 .- 0250-8095. ; 50:5, s. 345-356
-
Tidskriftsartikel (refereegranskat)abstract
- <b><i>Background:</i></b> Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. <b><i>Patients and</i></b> <b><i>Methods:</i></b> The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate ≥25 mL/min/1.73 m<sup>2</sup> and albuminuria (urinary albumin-to-creatinine ratio ≥30 to ≤5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level α = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. <b><i>Conclusions:</i></b> FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049.
|
|
| 2. |
|
|
| 3. |
- Herranz, L. E., et al.
(författare)
-
The working group on the analysis and management of accidents (WGAMA) : A historical review of major contributions
- 2020
-
Ingår i: Progress in nuclear energy (New series). - : PERGAMON-ELSEVIER SCIENCE LTD. - 0149-1970 .- 1878-4224. ; 127
-
Forskningsöversikt (refereegranskat)abstract
- The Working Group on the Analysis and Management of Accidents (WGAMA) was created on December 31st' 1999 to assess and strengthen the technical basis needed for the prevention, mitigation and management of potential accidents in NPP and to facilitate international convergence on safety issues and accident management analyses and strategies. WGAMA addresses reactor coolant system thermal-hydraulics, in-vessel behaviour of degraded cores and in-vessel protection, containment behaviour and containment protection, and fission product (FP) release, transport, deposition and retention, for both current and advanced reactors. As a result, WGAMA contributions in thermal-hydraulics, computational fluid-dynamics (CFD) and severe accidents along the first two decades of the 21st century have been outstanding and are summarized in this paper. Beyond any doubt, the Fukushima-Daiichi accident heavily impacted WGAMA activities and the substantial outcomes produced in the accident aftermath are neatly identified in the paper. Beyond specific events, most importantly, around 50 technical reports have become reference material in the different fields covered by the group and they are gathered altogether in the reference section of the paper; a common outstanding feature in most of these reports is the recommendations included for further research, some of which have eventually given rise to some of the projects conducted or underway within the OECD framework. Far from declining, ongoing WGAMA activities are numerous and a number of them is already planned to be launched in the near future; a short mention to them is also included in this paper.
|
|
| 4. |
- Karim, QA, et al.
(författare)
-
Women for science and science for women: Gaps, challenges and opportunities towards optimizing pre-exposure prophylaxis for HIV-1 prevention
- 2022
-
Ingår i: Frontiers in immunology. - : Frontiers Media SA. - 1664-3224. ; 13, s. 1055042-
-
Tidskriftsartikel (refereegranskat)abstract
- Preventing new HIV infections remains a global challenge. Young women continue to bear a disproportionate burden of infection. Oral pre-exposure prophylaxis (PrEP), offers a novel women-initiated prevention technology and PrEP trials completed to date underscore the importance of their inclusion early in trials evaluating new HIV PrEP technologies. Data from completed topical and systemic PrEP trials highlight the role of gender specific physiological and social factors that impact PrEP uptake, adherence and efficacy. Here we review the past and current developments of HIV-1 prevention options for women with special focus on PrEP considering the diverse factors that can impact PrEP efficacy. Furthermore, we highlight the importance of inclusion of female scientists, clinicians, and community advocates in scientific efforts to further improve HIV prevention strategies.
|
|
| 5. |
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
|
|
| 9. |
|
|
| 10. |
|
|
